These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 26630134)

  • 1. Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment Stratification.
    Krug S; Boch M; Daniel H; Nimphius W; Müller D; Michl P; Rinke A; Gress TM
    PLoS One; 2015; 10(12):e0143822. PubMed ID: 26630134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of dihydropyrimidine-dehydrogenase and thymidylate-synthase in patients with pancreatic neuroendocrine neoplasms treated with 5-FU-based chemotherapy.
    Krug S; Boch M; Nimphius W; Gress TM; Michl P; Rinke A
    Pancreatology; 2017; 17(1):139-145. PubMed ID: 28027897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low dose DTIC is effective and safe in pretreated patients with well differentiated neuroendocrine tumors.
    Mueller D; Krug S; Majumder M; Rinke A; Gress TM
    BMC Cancer; 2016 Aug; 16():645. PubMed ID: 27538897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours.
    Dilz LM; Denecke T; Steffen IG; Prasad V; von Weikersthal LF; Pape UF; Wiedenmann B; Pavel M
    Eur J Cancer; 2015 Jul; 51(10):1253-62. PubMed ID: 25935542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Therapy Sequence with Alkylating Agents and MGMT Status in Patients with Advanced Neuroendocrine Tumors.
    Krug S; Boch M; Rexin P; Gress TM; Michl P; Rinke A
    Anticancer Res; 2017 May; 37(5):2491-2500. PubMed ID: 28476818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multi-center clinical evaluation of streptozocin-based chemotherapy for advanced pancreatic neuroendocrine tumors in Japan: focus on weekly regimens and monotherapy.
    Shibuya H; Hijioka S; Sakamoto Y; Ito T; Ueda K; Komoto I; Kobayashi N; Kudo A; Yasuda H; Miyake H; Arita J; Kiritani S; Ikeda M; Imaoka H; Ueno M; Kobayashi S; Furuta M; Nagashio Y; Murohisa G; Aoki T; Matsumoto S; Motoya M; Azemoto N; Itakura J; Horiguchi S; Yogi T; Kawagoe T; Miyaoka Y; Imamura F; Senju M; Arioka H; Hara K; Imamura M; Okusaka T
    Cancer Chemother Pharmacol; 2018 Oct; 82(4):661-668. PubMed ID: 30054710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorouracil, Doxorubicin with Streptozocin and Subsequent Therapies in Pancreatic Neuroendocrine Tumors.
    Rogers JE; Lam M; Halperin DM; Dagohoy CG; Yao JC; Dasari A
    Neuroendocrinology; 2022; 112(1):34-42. PubMed ID: 33434908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Streptozocin and 5-Fluorouracil for the Treatment of Pancreatic Neuroendocrine Tumors: Efficacy, Prognostic Factors and Toxicity.
    Clewemar Antonodimitrakis P; Sundin A; Wassberg C; Granberg D; Skogseid B; Eriksson B
    Neuroendocrinology; 2016; 103(3-4):345-53. PubMed ID: 26279284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Streptozocin/5-fluorouracil chemotherapy of pancreatic neuroendocrine tumours in the era of targeted therapy.
    Lahner H; Mathew A; Klocker AL; Unger N; Theysohn J; Rekowski J; Jöckel KH; Theurer S; Schmid KW; Herrmann K; Führer D
    Endocrine; 2022 Jan; 75(1):293-302. PubMed ID: 34480724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival.
    Gupta S; Johnson MM; Murthy R; Ahrar K; Wallace MJ; Madoff DC; McRae SE; Hicks ME; Rao S; Vauthey JN; Ajani JA; Yao JC
    Cancer; 2005 Oct; 104(8):1590-602. PubMed ID: 16134179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy for Well-Differentiated Pancreatic Neuroendocrine Tumours with a Ki-67 Index ≥10%: Is There a More Effective Antitumour Regimen? A Retrospective Multicentre Study of the French Group of Endocrine Tumours (GTE).
    Roquin G; Baudin E; Lombard-Bohas C; Cadiot G; Dominguez S; Guimbaud R; Niccoli P; Legoux JL; Mitry E; Rohmer V; Ruszniewski P; Walter T; Ducreux M; Couvelard A; Scoazec JY; Ramond-Roquin A; Caroli-Bosc FX; Hentic O
    Neuroendocrinology; 2018; 106(1):38-46. PubMed ID: 28152531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the combination 5-fluorouracil, dacarbazine, and epirubicin in patients with advanced well-differentiated neuroendocrine tumors.
    Walter T; Bruneton D; Cassier PA; Hervieu V; Pilleul F; Scoazec JY; Chayvialle JA; Lombard-Bohas C
    Clin Colorectal Cancer; 2010 Oct; 9(4):248-54. PubMed ID: 20920998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan.
    Aoki T; Kokudo N; Komoto I; Takaori K; Kimura W; Sano K; Takamoto T; Hashimoto T; Okusaka T; Morizane C; Ito T; Imamura M
    J Gastroenterol; 2015 Jul; 50(7):769-75. PubMed ID: 25348496
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)--a phase II non-randomised trial.
    Ducreux M; Dahan L; Smith D; O'Toole D; Lepère C; Dromain C; Vilgrain V; Baudin E; Lombard-Bohas C; Scoazec JY; Seitz JF; Bitoun L; Koné S; Mitry E
    Eur J Cancer; 2014 Dec; 50(18):3098-106. PubMed ID: 25454412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Cytotoxic Chemotherapy in Advanced Pancreatic Neuroendocrine Tumors.
    Krug S; Gress TM; Michl P; Rinke A
    Digestion; 2017; 96(2):67-75. PubMed ID: 28728148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors.
    O'Toole D; Couvelard A; Rebours V; Zappa M; Hentic O; Hammel P; Levy P; Bedossa P; Raymond E; Ruszniewski P
    Endocr Relat Cancer; 2010 Dec; 17(4):847-56. PubMed ID: 20570957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases.
    Hur S; Chung JW; Kim HC; Oh DY; Lee SH; Bang YJ; Kim WH
    J Vasc Interv Radiol; 2013 Jul; 24(7):947-56; quiz 957. PubMed ID: 23602421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.
    Sun W; Lipsitz S; Catalano P; Mailliard JA; Haller DG;
    J Clin Oncol; 2005 Aug; 23(22):4897-904. PubMed ID: 16051944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of weekly streptozocin and oral S-1 treatment for patients of unresectable or metastatic pancreatic neuroendocrine neoplasms.
    Ono H; Kudo A; Akahoshi K; Ogura T; Ogawa K; Ban D; Tanaka S; Tanabe M
    J Cancer Res Clin Oncol; 2020 Mar; 146(3):793-799. PubMed ID: 31844980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.